Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
News Source : Forbes
News Summary
- Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies.
- Now it’s in talks to raise $400 million more VC funding at a $3.4 billion valuation.
- In January, the startup announced a deal with Eli Lilly, the $1 trillion (market cap) drug behemoth best known for its weight-loss drugs.
- Chai is in talks with more than 15 additional pharma companies, and hopes to sign more deals this year.
Never miss a story from us, subscribe to our newsletter